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Abstract
Background: Desmoid tumours or fibromatoses are rare entities characterized by the benign
proliferation of fibroblasts, which can be life-threatening due to their locally aggressive properties.
Surgery is widely accepted as the first line of treatment for extra-abdominal desmoids; however, it
is not recommended for intra-abdominal desmoids because of the high-risk of recurrence and
difficulties with the operation. Here, we report on a patient with sporadic intra-abdominal desmoid
tumours, who showed partial response following the intake of non-steroidal anti-inflammatory
drugs.
Case presentation: A 73-year-old man presented with swelling and pain of the right leg.
Computed tomography showed an abnormal multilocular soft-tissue mass (95 × 70 mm) in the
right pelvis, which was revealed by biopsy to be a desmoid tumour. Immunohistochemical analysis
showed that the tumour cells expressed vimentin, but not smooth-muscle actin, CD34, or desmin.
Very few Ki-67-positive cells were found. Non-cytotoxic treatment with etodolac (200 mg/day)
was chosen because of the patient's age, lack of bowel obstruction, and the likelihood of prostate
cancer. Two years after the commencement of non-steroidal anti-inflammatory drug
administration, computed tomography showed a decrease in tumour size (63 × 49 mm), and the
disappearance of intratumoural septa.
Conclusion:  Our case report suggests that non-steroidal anti-inflammatory drug treatment
should be taken into consideration for use as first-line treatment in patients with sporadic intra-
abdominal desmoid tumours.
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Background
Desmoid tumours or aggressive fibromatoses are rare soft
tissue neoplasms that can occur sporadically or in associ-
ation with familial adenomatous polyposis (FAP). These
tumours are aggressive, infiltrative, and destructive, and
can recur frequently, although they do not metastasise [1].
The aetiology of these tumours is unknown, but genetic,
hormonal (e.g., deterioration triggered by pregnancy),
and physical factors (e.g., previous surgery) play a role in
their development and growth. A distinction is often
made between desmoids in patients with FAP and those
in patients without FAP, but clinically these tumours are
treated the same; the only difference is the preferential
intra-abdominal location of FAP desmoids.
Surgery is the mainstay treatment for extra-abdominal
and abdominal-wall desmoids; however, is not recom-
mended for intra-abdominal desmoids because of the
high-risk of recurrence and the difficulties associated with
the operation. Recently, we have shown that the chemo-
therapeutic modality of doxorubicin plus dacarbazine is
efficacious and safe for desmoid patients with FAP [2].
After all, the main aim of desmoid treatment is local con-
trol. Several pharmacological agents have successfully
been used to treat desmoids, including anti-oestrogen and
non-steroidal anti-inflammatory drugs (NSAIDs) [1].
NSAIDs efficiently block cyclooxygenase (COX) activity
and are well known to be beneficial in the prevention of
colorectal carcinogenesis including FAP.Here, we report
on a patient with sporadic intra-abdominal desmoid
tumours, who underwent non-cytotoxic NSAID therapy
and showed remarkable regression. To our knowledge,
this is the first report demonstrating the potency of
NSAIDs for both FAP-associated desmoids and sporadic
desmoid tumours.
Case presentation
A 73-year-old man presented with pain and swelling of
the right leg. Computed tomography (CT) and magnetic
resonance imaging (MRI) showed an abnormal multiloc-
ular soft tissue mass (95 × 70 mm) in the right pelvis,
which was suspected of lymphoma or lymph node metas-
tasis (Figure 1). The patient had not undergone previous
surgery, had no family history of colorectal cancer or pol-
yps, and showed no abnormality on colonoscopy. On
clinical admission, a CT-guided biopsy revealed the intra-
abdominal mass to be a desmoid tumour. Non-cytotoxic
treatment was chosen because of the patient's age, lack of
bowel obstruction, and the likelihood for prostate cancer.
Initial treatment commenced with administration of the
COX-2 inhibitor, meloxicam. However, the patient expe-
rienced hot flushes, so treatment was changed to an alter-
native COX-2 inhibitor, etodolac (200 mg/day). After two
years of the commencement of etodolac, CT showed a
decrease in tumour size (to 63 × 49 mm) along with dis-
appearance of intratumoural septa. Regression rate of par-
tial response (PR) was 68.5%, and no adverse events were
reported.
Histological examination
Microscopic examination of the biopsy specimen revealed
spindle-cellular tumours surrounding muscular elements.
The tumour cells had a pale eosinophilic cytoplasm and
chromatin structures, and were embedded in a collagen
network interrupted by fibrotic sections (Figure 2). Immu-
nohistochemical analysis showed that the tumour cells
expressed vimentin, but not smooth-muscle actin (SMA),
CD34, or desmin. Very few Ki-67-positive cells were
found. After the diagnosis of desmoid tumour, analysis of
β-catenin expression could not be undertaken because of
an insufficient sample volume.
Discussion
In patients with FAP, desmoid tumours are caused by a
mutation of the adenomatous polyposis coli (APC) gene [3].
By contrast, 75% of desmoid tumour patients without
FAP harbour a somatic mutation in either the APC or β-
catenin genes, resulting in β-catenin protein stabilisation
[3-5]. Several NSAIDs have been shown to inhibit the
activity of β-catenin-dependent reporter genes in malig-
nant cell lines, and to induce β-catenin degradation [6,7].
Moreover, NSAIDs appear to inhibit the initial stages of
the colorectal adenoma-carcinoma sequence, suggesting a
link to the APC/β-catenin/TCF pathway (Wnt-signalling
pathway), and the colonic polyps of patients treated with
NSAIDs demonstrate reduced nuclear accumulation of β-
catenin [6]. Oncogenic activation of the Wnt-signalling
pathway by mutations in APC or β-catenin, which results
in the accumulation and nuclear translocation of β-cat-
enin and in β-catenin/TCF4-regulated transcription of
TCF target genes, is mandatory for the initial neoplastic
transformation of intestinal epithelium [8,9]. The basic
and clinical data imply that NSAIDs inhibit β-catenin
activity or its stability. Theoretically, NSAIDs may, hence,
have the potency to inhibit the development of some
desmoid tumours via interference of β-catenin function,
although the biochemical basis for these effects has not
been clarified.
The treatment of desmoid tumours remains enigmatic
despite longstanding investigation. However, it appears
that analysis of APC/β-catenin expression in desmoid
tumours might determine the efficacy of NSAIDs, and
contribute to tumour-growth inhibition and survival in
desmoid patients with β-catenin protein stabilisation.
Surgical treatment is difficult and requires a wide resec-
tion margin to prevent tumour recurrences. Desmoid
tumours are locally invasive lesions that do not metasta-
sizes; thus, a decrease in the growth rate could prevent the
need for more radical treatments, which would be benefi-World Journal of Surgical Oncology 2008, 6:17 http://www.wjso.com/content/6/1/17
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cial for elderly patients in poor general condition. At our
institution, a chemotherapeutic regimen of doxorubicin
plus dacarbazine is the preferred first-line treatment for
FAP-associated unresectable intra-abdominal desmoids.
However, its application is restricted to patients with
symptoms of bowel obstruction. Other patients are
treated initially with COX-2 inhibitors. In the present
case, the tumour demonstrated PR following treatment
with etodolac, even though the COX-2 selectivity of this
NSAID is far weaker than that of meloxicam. The patient
was offered no additional therapy, and remained asymp-
tomatic even after two year of follow-up, without any evi-
dence of deterioration. This suggests that the COX-2
selectivity of NSAIDs might not be critical for determining
inhibitory effect against desmoid tumours.
Surgery is the treatment of choice for patients with
desmoids loco-regionally confined to the body wall.
However, surgical excision provides for only a narrow
therapeutic window, when desmoid tumours are located
in the abdominal cavity and recur even if they are not
associated with FAP. Therefore, the efficient blockade of β-
catenin by NSAIDs might be useful in achieving signifi-
cant and durable cytoreduction, obviating the need for
surgical intervention in patients with sporadic desmoid
tumour as well as those with FAP-associated desmoids,
especially when they show a high risk of operation (gen-
eral condition, age, complication, quality of life, etc.)
Continued efforts at improving the efficacy of such regi-
mens with possible addition of novel molecule-targeting
agents should be made in the future.
Desmoid tumour before (A, C) and 2 years after (B, D) the commencement of NSAID Figure 1
Desmoid tumour before (A, C) and 2 years after (B, D) the commencement of NSAID. Multi planner reformation 
(MPR)-CT demonstrates the sporadic desmoid tumours originating from the intra-abdominal cavity (arrows). Frontal (A, B) 
and axial (C, D) images are shown. The tumour has shown a remarkable shrinkage with a regression rate of 68.5% along with 
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Conclusion
This is the first report of a patient with sporadic desmoid
tumour who has shown PR following the administration
of an NSAID alone. Our case report suggests that NSAID
treatment should be considered for use as a first-line treat-
ment in patients with sporadic intra-abdominal desmoid
tumours and a high risk general condition, as well as
those with FAP-associated desmoids.
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Microscopic examination of biopsy specimen Figure 2
Microscopic examination of biopsy specimen. Spindle-
cellular tumours surrounded muscle components. The 
tumour cells had pale eosinophilic cytoplasms and chromatin 
structures, and were embedded in a collagen network inter-
rupted by fibrotic sections. Scale bar represents 100 µm.